oncolyticsbiotech.com oncolyticsbiotech.com

oncolyticsbiotech.com

Oncolytics Biotech, Inc. (ONCYF)

What Does REOLYSIN Do? Oncolytics Biotech Inc. is developing REOLYSIN , a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. How We're Developing REOLYSIN as an. Taking advantage of stressed tumor cells to initiate cell lysis.

http://www.oncolyticsbiotech.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR ONCOLYTICSBIOTECH.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

September

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Sunday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 16 reviews
5 star
9
4 star
4
3 star
1
2 star
0
1 star
2

Hey there! Start your review of oncolyticsbiotech.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.5 seconds

FAVICON PREVIEW

  • oncolyticsbiotech.com

    16x16

  • oncolyticsbiotech.com

    32x32

CONTACTS AT ONCOLYTICSBIOTECH.COM

Oncolytics Biotech Inc.

210, 1167 ●●●●●●●●●●n Cr. N.W.

Ca●●ry , AB, T2N 1X7

CA

403.●●●●7381
no●●●●●●●●●●●●@worldnic.com

View this contact

Oncolytics Biotech Inc.

Oncolytics Biotech Inc.

210, 1167 ●●●●●●●●●●n Cr. N.W.

Ca●●ry , AB, T2N 1X7

CA

403.●●●●7381
sb●●●●@oncolytics.ca

View this contact

Oncolytics Biotech Inc.

Oncolytics Biotech Inc.

210, 1167 ●●●●●●●●●●n Cr. N.W.

Ca●●ry , AB, T2N 1X7

CA

403.●●●●7381
sb●●●●@oncolytics.ca

View this contact

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED
2000 February 24
UPDATED
2013 December 16
EXPIRATION
EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

Network Solutions®

DOMAIN AGE

  • 25

    YEARS

  • 3

    MONTHS

  • 5

    DAYS

NAME SERVERS

1
ns41.worldnic.com
2
ns42.worldnic.com

REGISTRAR

NETWORK SOLUTIONS, LLC.

NETWORK SOLUTIONS, LLC.

WHOIS : whois.networksolutions.com

REFERRED : http://networksolutions.com

CONTENT

SCORE

6.2

PAGE TITLE
Oncolytics Biotech, Inc. (ONCYF) | oncolyticsbiotech.com Reviews
<META>
DESCRIPTION
What Does REOLYSIN Do? Oncolytics Biotech Inc. is developing REOLYSIN , a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. How We're Developing REOLYSIN as an. Taking advantage of stressed tumor cells to initiate cell lysis.
<META>
KEYWORDS
1 our company
2 management team
3 board of directors
4 collaborators
5 technology
6 what is reolysin
7 delivery
8 intellectual property
9 posters and publications
10 manufacturing
CONTENT
Page content here
KEYWORDS ON
PAGE
our company,management team,board of directors,collaborators,technology,what is reolysin,delivery,intellectual property,posters and publications,manufacturing,clinical trials,clinical development plan,studies,news,investors,overview,stock information,faqs
SERVER
Apache
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Oncolytics Biotech, Inc. (ONCYF) | oncolyticsbiotech.com Reviews

https://oncolyticsbiotech.com

What Does REOLYSIN Do? Oncolytics Biotech Inc. is developing REOLYSIN , a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. How We're Developing REOLYSIN as an. Taking advantage of stressed tumor cells to initiate cell lysis.

INTERNAL PAGES

oncolyticsbiotech.com oncolyticsbiotech.com
1

Leading Clinical-Stage Oncology Company | Oncolytics Biotech Inc

https://www.oncolyticsbiotech.com/for-investors/analyst-coverage/default.aspx

News & Events. Oncolytics Biotech Inc. is a clinical-stage oncology company focused on the development of oncolytic viruses for use as cancer therapeutics in some of the most prevalent forms of the disease. Our lead product, REOLYSIN. Is currently entering into late stage (Phase III) clinical testing. Learn More About REOLYSIN. Sign up to receive email updates. For Patients and Doctors. WATCH THE MOA VIDEO. Find a Clinical Trial. What Are Oncolytic Viruses? How Do Clinical Trials Work? Aug 30, 2016.

2

RSS Feeds – Investor Centre | Oncolytics Biotech Inc

https://www.oncolyticsbiotech.com/for-investors/rss-feeds/default.aspx

News & Events. Press Release RSS Feed. Really Simple Syndication (RSS) is a technology that allows you to receive updated news from preferred websites, which are sent directly to the user’s news reader. This includes the headlines, summaries and links to the full article on the website. What are the benefits of using RSS? How can I sign up to RSS feeds? August 30, 2016. Media Advisory – Oncolytics Biotech. Inc Announces Participation in the 4th Annual Immuno-Oncology Summit. August 10, 2016. Aug 30, 2016.

3

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics – Oncolytics Biotech Inc.

https://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Collaborators-Present-REOLYSIN-Preclinical-Data-at-the-9th-International-Conference-on-Oncolytic-Virus-Therapeutics/default.aspx

News & Events. Inc Collaborators Present REOLYSIN. Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics. News & Events. Oncolytics Biotech Inc. Collaborators Present REOLYSIN Preclinical Data at the. June 15, 2015. June 15, 2015. CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a series of oral and poster presentations are being made by the Company's research collaborators at the 9. 2015 in Boston MA. The first abstract/poster titl...

4

Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer – Oncolytics Biotech Inc.

https://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Collaborators-Present-Final-Data-from-REO-017-Clinical-Study-in-Pancreatic-Cancer/default.aspx

News & Events. Inc Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer. News & Events. Oncolytics Biotech Inc. Collaborators Present Final Data from REO 017. July 6, 2015. Report More Than Doubling in One-Year Survival and Nearly Five-Fold Increase in Two-Year Survival as Compared to Historical Controls-. July 6, 2015. CNW/ - Oncolytics Biotech. COO of Oncolytics. "The observation of clear overall survival (OS) benefit combined with apparent limited impact on progression...

5

Investor Overview | Oncolytics Biotech Inc.

https://www.oncolyticsbiotech.com/for-investors

News & Events. The Cutting Edge of Cancer Innovation. Oncolytics Biotech Inc. is a developer of oncolytic viruses as cancer therapeutics and is listed on the Toronto Stock Exchange (TSX:ONC. The OTCQX Best Market (OTCQX:ONCYF) and the Frankfurt Stock Exchange (FRA:ONY). In addition to the information available on this site, investors can access the Company’s regulatory filings on the SEDAR website at www.sedar.com. And on the EDGAR website at www.sec.gov. VIEW ALL STOCK INFORMATION. August 30, 2016.

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

LINKS TO THIS WEBSITE

virotherapy.eu virotherapy.eu

In the World | Virotherapy.eu

http://www.virotherapy.eu/in-the-world.html

This section is intended as a portal with Internet resources, latest publications, events and activities in the field of virotherapy around the world. Here everyone will be able to make sure of the wide scale of virotherapy, high level of development, and the actual future perspectives of saving the humankind from cancer. Please, send the information to info@virotherapy.eu. Internet resources and publications:. Http:/ ruscur.ru/articles/2013/12/20/since.shtml. Http:/ www.oncolyticsbiotech.com/. Http:/ ww...

viral-lovers.blogspot.com viral-lovers.blogspot.com

viral lovers: August 2009

http://viral-lovers.blogspot.com/2009_08_01_archive.html

Because viruses need love too . . . Tuesday, 4 August 2009. Oncolytic viruses . . . are out the gate - at least in China. Modified Vaccinia Ankara (MVA) - induce immune response against tumour ass. Antigen 5T4. 5T4 tumour antigen is a unique target, which is expressed at high levels in the majority of epithelial-derived cancers such as colorectal (85%), renal, prostate, lung and breast. . . . .treatment of Parkinson’s disease. C. Vaccinia virus. S. Phase I - advanced solid organ cancer. Private. PhaseIII...

UPGRADE TO PREMIUM TO VIEW 61 MORE

TOTAL LINKS TO THIS WEBSITE

63

SOCIAL ENGAGEMENT



OTHER SITES

oncolysis.net oncolysis.net

oncolysis.net

oncolysis.org oncolysis.org

oncolysis.org

oncolyticimmunotherapy.com oncolyticimmunotherapy.com

Find it | Fight It | Lyse & Learn. Explore Oncolytic Immunotherapy

Website is under maintenance. Please check back later.

oncolytics.blogspot.com oncolytics.blogspot.com

The Oncolytic Times: Oncolytics Biotech News and Information

Tuesday, August 12, 2008. US NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with Reolysin. The primary objectives of the study are to assess the antitumour effects of Reolysin in patients with metastatic malignant melanoma, as well as the safety profile of Reolysin. Secondary objectives include assessment of progression free survival and overall survival. Approximately 60,000 people are diagnosed with melanoma in the U.S. every year. Wednesday, July 30, 2008. Oncolytics experienced a st...

oncolytics.ca oncolytics.ca

http://oncolytics.ca/

To view the non-framed versi on.

oncolyticsbiotech.com oncolyticsbiotech.com

Oncolytics Biotech, Inc. (ONCYF)

What Does REOLYSIN Do? Oncolytics Biotech Inc. is developing REOLYSIN , a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. How We're Developing REOLYSIN as an. Taking advantage of stressed tumor cells to initiate cell lysis.

oncolyticvirotherapies.com oncolyticvirotherapies.com

Oncolytic Virotherapy Summit 2017 | Hanson Wade

December 5-6th, 2017. San Diego, CA. The Annual Oncolytic Virotherapy Summit is dedicated to foster the next wave of genetically modified viruses. That target, replicate and kill cancer cells in a clinical setting, spurred on by advanced genetic engineering techniques. By better understanding o ncolytic platforms, preclinical virotherapy models, clinical strategy and scalable manufacture. Of viruses, Oncolytic Virotherapy Summit is the only industry-focused gathering. T: 44 (0)20 3141 8700. San Diego, CA.

oncolyticvirus.com oncolyticvirus.com

oncolyticvirus.com

The domain oncolyticvirus.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

oncolyticvirus.info oncolyticvirus.info

アコム審査基準ナビ〜甘いって本当?主婦もバイトも学生も即日融資可能!

パートやアルバイトなどでしっかり収入があるのに 職歴が短い 自営業だから 納得の行かない理由で、キャッシングやクレジットカードを諦めていませんか. クレジットカードの審査は、一般的に金融系 流通系 信販系 銀行系の順番で規準が厳しいと言われています。 本当は返済能力のあるのに、雇用期間の短さなどで審査に落とされてしまうのは、悔しくはありませんか アコムなら、その点をしっかり審査してくれます クレジットカードの審査を恐れてはダメ まずは、3秒審査にトライ 審査回答も最短たったの30分.

oncolyticvirus.wordpress.com oncolyticvirus.wordpress.com

Developing oncolytic virus therapies | The next wave views from Oncos Therapeutics

Developing oncolytic virus therapies. The next wave views from Oncos Therapeutics. Posted by: Lotta Kangasniemi. March 23, 2011. About viruses and cancer immunotherapy. Immunotherapeutics is said to be the most likely field for the next major breakthrough in cancer. The first FDA-approved therapeutic cancer vaccine Provenge. Rapidly accumulating clinical and immunological information enables rationale-driven vector design and improved treatment protocols. Given the recent advances and excitement in t...

oncolyticvirusmeeting.weebly.com oncolyticvirusmeeting.weebly.com

8th International meeting on - Home

Accommodation at Lincoln College. Additional Accommodation) Merton College. Additional Accommodation) Jesus College. 8th International meeting on. Follow us on Facebook and Twitter. Welcome to the website of the. 8th International Conference on Oncolytic Virus Therapeutics. If you would like to be added to a waiting list. For available places, please email. STOP PRESS: THE ROYAL COLLEGE OF PHYSICIANS HAVE AWARDED. 24 CPD POINTS FOR FULL ATTENDANCE AT THIS MEETING. List of recipients can be found here.